Novel Thioxothiazolo[3,4-a]quinazolin-5(4H)-one Derivatives as BKCa Channel Activators for Urinary Incontinence DOI
Eun Jung Bae,

Heeji Jo,

Seong Soon Kim

и другие.

ACS Medicinal Chemistry Letters, Год журнала: 2022, Номер 13(7), С. 1052 - 1061

Опубликована: Июнь 21, 2022

Overactive bladder (OAB) is a syndrome causing sudden and unstoppable need to urinate with significant global prevalence. Several drugs are used treat OAB; however, they have various side effects. Therefore, new treatment options for OAB required. A series of novel 5-oxo-N-phenyl-1-thioxo-4,5-dihydro-1H-thiazolo[3,4-a]quinazoline-3-carboxamide derivatives were synthesized evaluated their large-conductance voltage- Ca2+-activated K+ channel activation through cell-based fluorescence assay electrophysiological recordings. compounds, including 7-bromo substituent on the heterocyclic system, showed increased currents. Among derivatives, compound 12h exhibited potent in vitro activity half-maximal effective concentration (EC50) 2.89 μM, good oral pharmacokinetic properties (area under curve half-life), vivo efficacy spontaneously hypertensive rat model.

Язык: Английский

Lower urinary tract dysfunction in uncommon neurological diseases: A report of the neurourology promotion committee of the International Continence Society DOI Creative Commons
Blayne Welk, Ryuji Sakakibara, Sanjay Sinha

и другие.

Continence, Год журнала: 2022, Номер 1, С. 100022 - 100022

Опубликована: Март 1, 2022

The management of patients with neurogenic lower urinary tract dysfunction has been well-described, however this is most frequently discussed for common conditions such as spinal cord injury or multiple sclerosis. Our objective was to review uncommon neurologic disorders and summarize both the underlying disease process, relevant disease-specific research on impact condition tract. Among degenerative traumatic brain disorders, we have included frontotemporal dementia, amyotrophic lateral sclerosis, Huntington's Disease, progressive supranuclear palsy, corticobasal degeneration, system atrophy, injury. autoimmune reviewed transverse myelitis, neuromyelitis optica spectrum Myelin oligodendrocyte glycoprotein antibody-associated disease, glial fibrillary acidic protein astrocytopathy, meningitis-retention syndrome (a form aseptic meningitis that presents retention). Hereditary spastic paraplegia, VACTERL association, several peripheral neuropathies (Guillain Barre syndrome, chronic inflammatory demyelinating polyneuropathy, autonomic gangliopathy, Wolfram disorder neuropathy early onset diabetes, optic atrophy megacystis in stage), Charcot Marie Tooth amyloid are included. Practice points specific where appropriate.

Язык: Английский

Процитировано

5

Efficacy and safety of mirabegron in the treatment of overactive bladder syndrome after radical prostatectomy: a prospective randomized controlled study DOI Creative Commons
Wang Li,

Yanduo Lin,

Hong Xie

и другие.

Frontiers in Oncology, Год журнала: 2023, Номер 13

Опубликована: Май 2, 2023

To evaluate the effects of mirabegron in treatment overactive bladder syndrome (OAB) after radical prostatectomy (RP).A total 108 post-operative RP patients were randomly assigned to either (study) or placebo (control) group. The Overactive Bladder Syndrome Self-Assessment Scale (OABSS) was selected as primary endpoint, and International Prostate Symptom Score (IPSS) Quality Life (QOL) score secondary endpoints. Statistical analysis performed using IBM SPSS Statistics 26, compared between two groups independent samples t-test.In total, 55 included study group 53 control mean age was(70.08 ± 7.54)years. There no statistical difference baseline data groups. OABSS scores decreased significantly during drug (6.67 1.06 vs. 9.14 1.83, p < 0.01) better than follow-up at week 8 12. In addition, decrease IPSS (11.29 3.89 15.34 3.54, p<0.01) increase QOL (2.40 0.81 3.20 1.00) statistically significant And had improvement voiding symptoms quality life period.Daily administration 50 mg surgery improved OAB with fewer side effects. Additional randomized controlled trials should be conducted future further efficacy safety mirabegron.

Язык: Английский

Процитировано

2

The Impact of Polypharmacy on Management of Lower Urinary Tract Symptoms in Parkinson’s Disease DOI
Udit Saraf, Amit Batla, Ryuji Sakakibara

и другие.

Drugs & Aging, Год журнала: 2023, Номер 40(10), С. 909 - 917

Опубликована: Авг. 31, 2023

Язык: Английский

Процитировано

2

Despite Recommendations, Anticholinergics Account for the Majority of Prescriptions to Treat Overactive Bladder in the United States DOI

Danielle Carr,

Annliz Macharia,

Michele R. Hacker

и другие.

Urogynecology, Год журнала: 2022, Номер 29(5), С. 497 - 503

Опубликована: Ноя. 12, 2022

Importance There are significant associations between anticholinergic medication use and an increased risk of cognitive impairment dementia. Many experts now advocate minimizing the medications to treat overactive bladder (OAB) in elderly women. Objective The aim this study was describe temporal geographic trends pharmacologic treatment OAB for patients 65 years or older across United States. Study Design U.S. Centers Medicare & Medicaid Services publishes annual Provider Utilization Payment Data. data set includes number unique Part D beneficiaries with at least 1 claim a drug 30-day fills dispensed. database also state rural-urban commuting area designation prescriber. Results From 2013 2019, received 47.7 million OAB. In 2013, anticholinergics represented 98% total (5.6 million) β3 agonists nearly 24 times greater 2019 than 2013. Geographic variation prescribing practices evident. Conclusions dispensed remained relatively stable, there substantial increase agonists. Percentages varied among states. More being treated OAB; however, comprised majority prescriptions 2019.

Язык: Английский

Процитировано

4

Novel Thioxothiazolo[3,4-a]quinazolin-5(4H)-one Derivatives as BKCa Channel Activators for Urinary Incontinence DOI
Eun Jung Bae,

Heeji Jo,

Seong Soon Kim

и другие.

ACS Medicinal Chemistry Letters, Год журнала: 2022, Номер 13(7), С. 1052 - 1061

Опубликована: Июнь 21, 2022

Overactive bladder (OAB) is a syndrome causing sudden and unstoppable need to urinate with significant global prevalence. Several drugs are used treat OAB; however, they have various side effects. Therefore, new treatment options for OAB required. A series of novel 5-oxo-N-phenyl-1-thioxo-4,5-dihydro-1H-thiazolo[3,4-a]quinazoline-3-carboxamide derivatives were synthesized evaluated their large-conductance voltage- Ca2+-activated K+ channel activation through cell-based fluorescence assay electrophysiological recordings. compounds, including 7-bromo substituent on the heterocyclic system, showed increased currents. Among derivatives, compound 12h exhibited potent in vitro activity half-maximal effective concentration (EC50) 2.89 μM, good oral pharmacokinetic properties (area under curve half-life), vivo efficacy spontaneously hypertensive rat model.

Язык: Английский

Процитировано

3